Please login to the form below

serelaxin

This page shows the latest serelaxin news and features for those working in and with pharma, biotech and healthcare.

New drugs can't keep Novartis sales on the up

year. A decision to drop development of acute heart failure drug serelaxin (RLX030) also pegged back Novartis' profits, forcing the company to take a charge of $200m in the quarter.

Latest news

What future for serelaxin after phase III miss?

What future for serelaxin after phase III miss? Novartis' acute heart failure therapy misses two main endpoints. ... credibility". Novartis had been hoping to build a valuable heart failure franchise around serelaxin for AHF and Entresto (sacubitril and
Novartis boosts cardiovascular pipeline with $1bn Ionis deal

The company launched first-in-class chronic heart failure therapy Entresto (sacubitril and valsartan) in 2015 and is hoping to re-file acute heart failure candidate serelaxin (RLX030) this year.
Novartis says Cosentyx is 'outpacing competitors'

These include RLX030 (serelaxin) for acute heart failure, Fovista (pegpleranib) and RTH258 (brolucizumab) for neovascular age-related macular degeneration (AMD), and novel migraine prevention drug AMG334.
Novartis will file heart failure drug before year-end

Novartis was less successful in its efforts to secure approval of acute heart failure therapy Reasanz (serelaxin), which was rejected by an FDA advisory committee earlier this year because of a
CHMP turns down Avastin for brain cancer

heart failure drug Reasanz (serelaxin).

More from news
Approximately 11 fully matching, plus 8 partially matching documents found.

Latest Intelligence

Heart failure therapy embarks on a new era

Other candidates in mid-stage testing include: natriuretic peptide receptor agonists from Capricor Therapeutics (cenderitide) and Palatin Technologies (PL-3994); Novartis' synthetic human relaxin 2 hormone serelaxin (knocked back by regulators
Interview: Elmar Schnee, Cardiorentis

It's a company with great potential, according to Schnee, who has high hopes for its lead drug candidate ularitide – an investigational product that is in competition with Novartis' serelaxin to ... Because of the serelaxin trial [by Novartis], you saw

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Medical Writers: Competitive Salary and Benefits

Programme Director, Healthcare PR, Highly competitive package: Highly Competitive package

Digital Manager, London – Healthcare Brandcomms, Medcomms, PR: Excellent package

Senior Account Managers - Oxfordshire: Attractive salary and benefits package offered

Senior Medical Writer (Remote Working): Competitive Salary Offered

Senior Medical Writer: Competitive Salary

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Leadership opportunity, Pricing & Market Access, UK, Substan...: Substantial six figure package

Senior Account Executive, London, Medical Communications: Excellent package

New Business Director - PR: Competitive Salary and benefits

Director, Market Access / HEOR - North-West: Negotiable

Senior Account Director development role to Business Director, H...: Excellent package

Events Manager – Med Comms – Surrey: Salary TBC

Production Manager – Healthcare Communications: DOE

Medical Writers Required – Cheshire: DOE

Senior Medical Writer: Great salary and benefits

Senior Account Manager: Negotiable

Account Director: £48, 000 - £60, 000

Associate Director, Market Access & HEOR – North-West: Negotiable

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Consumer Health Account Director: Circa £60, 000 Gym and More

Senior Systematic Review Analyst - Oxford: Negotiable

Medical/ Scientific Director: Salary TBC

Medical Writer – Health Behaviour/ Patient Adherence Agency: Salary TBC

Associate Medical Director: Highly Competitive

Subscribe to our email news alerts

PMHub

Add my company

W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

Innovation in merger control and the impact on the pharmaceutical sector: Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think: Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Quality in Care Diabetes 2018: the best in innovative diabetes care: Awards highlight new evidence-based approaches to improving care...